The biosynthesis of peptides requires the synthesis of the prohormone, several biosynthetic processing enzymes, and other granule constituents. We have investigated the regulated expression of proopiomelanocortin (POMC) and five enzymes essential for the processing of POMC to smaller, bloactive peptides in intermediate pituitary melanotropes. Rats were treated with a dopaminergic agonist (bromocriptine) or antagonist (haloperidol) for periods ranging from 1 h to 5 days, followed by analyses of mRNA levels and protein biosynthetic rates. Multiplex RNase protection assays showed that bromocriptine treatment caused a striking decrease in POMC mRNA levels, and significant decreases in mRNA levels for prohormone convertase 2 (PC2), carboxypeptidase H (CPH), and peptidylglycine a-amidating monooxygenase (PAM). Smaller increases in mRNA levels were seen after haloperidol stimulation. Protein biosynthetic rates changed more profoundly than mRNA levels at short drug treatment times, indicating a role for translational effects after treatment with bromocriptine and with haloperidol.
tract neurons (Civelli et al., 1982; Khachaturian et a!., 1985) . POMC processing is cell type specific, presumably reflecting tissue-specific expression of a set of granule-associated enzymes that includes prohormone convertases (PC1 and PC2), carboxypeptidase H (CPH), peptidylglycine a-amidating monooxygenase (PAM), and cytochrome b551 (Cytb561) (Mains and Eipper, 1990) (Fig. 1) .
All of the major endoproteolytic cleavages of POMC occur at pairs ofbasic amino acids and can be catalyzed by the subtilisin-like endoproteases PCi and PC2 (Benjannet et al., 1991; Lindberg, 1991; Thomas et al., 1991; Seidah and Chretien, 1992; Bloomquist and Mains, 1993; Zhou et al., 1993) . Corticotropes express primarily PC 1 mRNA, and melanotropes express high levels of PC2 mRNA along with PC 1 mRNA (Seidah et al., 1990; Bloomquist et al., 1991; Hakes et al., 1991; Day et al., 1992) . It is interesting that PCi and PC2 cleave POMC sequentially, with PCi catalyzing the initial steps of POMC processing and generating ACTH biosynthetic intermediate and /3-lipotropin ( Fig. 1) (Zhou et al., 1993) . These cleavages occur with similar kinetics in the anterior and intermediate lobes of the pituitary. PC2 then catalyzes the later steps in the biosynthetic pathway, which are restricted to melanotropes, generating Lys0-y3-melanotropin and /3-endorphin(1-27) (Mains and Eipper, 1990; Zhou et al., 1993) . Completion of POMC processing in the pituitary requires removal of Lys and Arg residues Biologically active peptides are synthesized from large, inactive precursors by a series of co-and posttranslational modifications (Mains and Eipper, 1990; Eipper et al., 1992; Seidah and Chretien, 1992; Seidah et al., 1993; Steiner et al., 1993a,b) . Proopiomelanocortin (POMC) , the common precursor to several peptide hormones, including adrenocorticotropic hormone (ACTH), a-melanotropin (a-MSH), and /3-endorphin, is synthesized in large amounts in anterior pituitary corticotropes, intermediate pituitary melanotropes, arcuate nucleus, and nucleus of the solitary (Mains and Eipper, 1990; Bloomquist et al., 1991; Zhou et al., 1993) . Steps catalyzed by CPH and PAM along with Cytb 561 are indicated. B: The lumen of the secretory granule is shown to the left of the lipid bilayer. The topology of Cytb561 is shown as determined by Fleming and Kent (1991) . The apparent molecular mass (kDa) and the number of methionine residues present in each promolecule are indicated (Fricker et al., 1989; Bloomquist et al., 1991; Srivastava et al., 1994) . The granule proteins are drawn to scale. ctMSH, a-melanotropin.
from the COOH-termini of the PCi and PC2 cleavage products by the exopeptidase CPH (Fricker, 1988) . After the action ofPCi, PC2, and CPH, PAM catalyzes the copper-, ascorbate-, and molecular oxygen-dependent a-amidation ofjoining peptide and a-MSH (Eipper et a!., 1992) . The level of ascorbate in the secretory granules is maintained by reduction of the semidehydroascorbate produced during the amidation reaction using electrons imported by the membrane-associated protein Cytb561 (Kent and Fleming, 1987) .
Because most of the enzymes catalyzing the major steps in POMC processing are known, it is now possible to identify rate-limiting steps and control points governing this peptidergic system. The intermediate pituitary is innervated by dopaminergic neurons that project from the hypothalamus (Ho!zbauer and Racke, i985; Davis, 1986) . D2-dopamine receptors, which play an important role in schizophrenia, Parkinson's disease, and tardive dyskinesia, are present at higher levels in the intermediate pituitary than in any other tissue (Bedard et a!., i986; Hoffman et a!., i989; Mengod et al., i989; Mansour et al., 1990) . To explore the mechanisms underlying dopaminergic regulation of POMC expression in the intermediate pituitary, rats have been treated chronically with either bromocriptine (a dopamine agonist) or haloperidol (a dopamine antagonist) (Ho!!t et al., i982; Chen et a!., 1983; Beaulieu et a!., 1984; Kelsey et a!., i986; Bloomquist et a!., 1991; Eipper et a!., 1992) . Me!anoptrope biosynthesis of POMC and its product peptides was increased slightly after 21 days of treatment with haloperidol and decreased dramatically after chronic treatment with bromocriptine . It is interesting that despite the >10-fold range in levels of POMC expression observed in bromocriptine-and haloperidol-treated animals, the same peptide products were produced in the same proportion. Recent data indicate that the expression of enzymes involved in POMC processing is regulated along with expression of POMC. Northern blot analysis of processing enzyme mRNAs after chronic drug treatment has shown that transcripts encoding PAM and CPH are up-regulated by haloperido! treatment and down-regulated by bromocriptine treatment Bloomquist eta!., 1991) . It is interesting that PCi and PC2 mRNA levels responded in the same manner as PAM, CPH, and POMC, indicating a coordinate regulation of peptide prohormone and processing enzyme mRNAs.
Based on studies involving a variety of stimuli, gene expression in peptidergic systems is also regulated on a time scale of hours (Sherman et a!., 1986; Bhat et a!., 1993) . The me!anotropes of the rat intermediate pituitary provide a relatively homogeneous cell system with which to investigate the effects of acute stimulation or inhibition by dopaminergic agents. In this study, we have investigated dopaminergic control of prohor-
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FIG.
2. RNase protection analysis of transcripts encoding granule-associated proteins. Total RNA isolated from neurointermediate pituitaries (n = 5 pituitaries/group) obtained from control rats (Oh), salinetreated rats, and rats treated once (4 h), twice (28 h), or five times with either bromocriptine (BROMO) or haloperidol (HALO) was assayed by RNase protection analysis for the presence of mRNA encoding P0MG, Phi, PC2, CPH, PAM, and Gytb 561. S26 ribosomal mRNA was used as an internal control. Antisense riboprobes ( 32P-labeled) were hybridized to 2.5-10 j.tg of total RNA or to known amounts of sense RNA and then digested with RNase as described in Materials and Methods. The protected fragments were fractionated on a 5% polyacrylamide gel containing 8 M urea and the size of each fragment was determined in reference to DNA markers (shown on left). The difference in the size of the sense and tissue protected pieces reflects the additional nucleotides present in the DNA template used for preparation of the probe and sense RNA. OTHER STD indicates the amounts of sense RNA used to determine the levels of PG1, PC2, PAM, CPH, Gytb 561, and S26 mRNAs.
mone and processing enzyme mRNA levels and biosynthetic rates by using RNase protection assays and metabolic labeling of me!anotropes followed by immunoprecipitation. For a subset of the processing enzymes, dopaminergic regulation affects translation as well as levels of individual mRNAs.
MATERIALS AND METHODS
Drug treatments and RNA isolation
Adult (175-250 g) ma!e Sprague-Dawley rats (Charles River, Wilmington, MA, U.S.A.) received five daily subcutaneous injections of bromocriptine (1 mg/kg/day), haloperidol (2 mg/kg/day), or saline (control) (Bloomquist et al., 1991) . All protocols were approved by the Animal Care and Use Committee. Rats were ki!led by decapitation 1 or 4 h after four saline injections and a single injection of drug (1-and 4-h treatments), 4 h after three dai!y injections of saline followed by two dai!y injections of drugs (28 h), or 4 h after five daily injections of drug (5 day), and neurointermediate lobes were separated from anterior lobes under a dissecting microscope. Total RNA from neurointermediate lobes was isolated using the RNAgents Tota! RNA Isolation Kit (Promega, Madison, WI, U.S.A.). In brief, neurointermediate pituitary tissue was homogenized in guanidine thiocyanate and then subjected to phenol/chloroform/isoamyl alcohol extraction and isopropano! precipitation. RNA was quantitated by absorbance at 260 nm and analyzedby formaldehyde-agarose gel e!ectrophoresis. An average of 5~g of total RNA per neurointermediate lobe was obtained.
In vitro transcription of riboprobes
A set of seven eDNA fragments were subcloned into the pB!uescript II SK-vector (Stratagene) by using either PCR or restriction endonucleases to remove the corresponding fragment from the original plasmid. The sizes of the cDNA inserts were selected to facilitate separation of the final protected RNA fragments by po!yacrylamide gel e!ectrophoresis (PAGE). The following eDNA fragments were subc!oned by using restriction endonucleases and used as templates for preparation of probe RNAs: PAM-solution hybridization (PAM-SH) [385 nucleotides (nt) Fig. 2 were quantified using a Phosphorlmager. The amount of each mRNA was normalized to the level of the internal control, S26 mRNA. The error bars represent mean ± SEM values of three independent experiments. Data points that differ significantly from control (p <0.05) are indicated by asterisks. HALO, haloperidol; BROMO, bromocriptine.
from a 1.4-kb rat CPH probe in pSP65 (Fricker et al., 1989) using two oligonucleotides, a 27-mer TCTAGACTGCTC-ACGAATACAGTTCCT that had an XbaI site (boldface) at the 5' end and an antisense 27-mer GGATCCACCGGG-GACGCTGTACCATG containing a BamHI site (boldface) at its 5' end. In addition, Cytb 561-SH [442 nt, rat equivalent to mCytb561(337-778 nt)} was amplified by reverse transcription-PCR of rat adrena! g!and RNA using two oligonucleotides complementary to the mouse sequence , a 28-mer GGATCCGCACGTCTTCGCCTT-CATCATC containing a BamHI site (boldface) at the 5' end and an antisense 26-mer GAATTCCATGGAGAG-GGCTTGCTCTT with an EcoRI site (boldface) at its 5' end. Each construct was verified by sequence ana!ysis.
In preparation for the synthesis of sense RNA standards and antisense riboprobes, the p!asmids were linearized either 5' or 3'to the eDNA insert, digested with 50~.tg/mlproteinase K (Boehringer Mannheim) at 37°Cfor 30 mm, and punfled by pheno!/chloroform extraction and ethanol precipitation. Linearized DNA templates (1 gig) were transcribed with 10 units of either T3 or T7 RNA polymerase, using an RNA transcription kit from Stratagene (La Jolla, CA, U.S.A.). For synthesis of high specific activity probes (ito 8 x !0~cpmI~.tg),the transcription reaction was set up in a fina! volume of 25~t1containing ix transcription buffer (200 mM Tris-HC1, pH 8.0, 40 mM MgC!2, 10 mM spermidine, 250 mM NaC!), 0.4 mM each of rATP, rGTP, and rCTP, 0.004 mM UTP, 0.03 mM dithiothreitol, 40 units RNase inhibitor (Promega, Madison, WI, U.S.A.), and 50 p~Ci [a 32P]UTP (400-800 Ci/mmol, NEN, Boston, MA, U.S.A.). After incubation for 30 mm at 37°C,2 units RNasefree DNase I was added and the reaction mixture was incubated for another 15 mm to remove p!asmid DNA template. The reaction volume was increased to 70~.tlwith STE (20 mM Tris-HC1, pH 7.5, 100 mM NaC!, 10 mM EDTA) and the radiolabeled transcript purified over a NucTrap column (Stratagene). POMC riboprobe was synthesized at a lower specific activity by using 0.04 mM rUTP in the reaction mixture. Probe size and integrity were checked on a 5% polyacrylamide gel containing 8 M urea.
Sense riboprobe standards for determining the levels of mRNA were synthesized as described above, but using 0.4 mM UTP; the amount of nboprobe was quantified by measuring absorbance at 260 nm after phenol/chloroform extraction and ethanol precipitation.
RNase protection assay
RNase protection assays were performed using the RPA II kit from Ambion (Austin, TX, U.S.A.). Total RNA (5-10 ,ug) and sense RNA (1-50 pg) were coprecipitated with 0.5-1 X 106 cpm of each 32P-labeled riboprobe in the presence of 10~.egof yeast RNA and air dried. Pel!ets were resuspended in 20 p~! of hybridization buffer (80% deionized formamide, 100 mM sodium citrate, pH 6.4, 300 mM sodium acetate, pH 6.4, 1 mM EDTA), heat denatured for 4 mm at 90°C,and hybridized to probe (1 X i0~cpm) at 44°Cover-.1. Neurochem., Vol. 67, No. 1, 1996 DOPAMINERGIC REGULATION OF PROCESSING ENZYMES 233 night. RNA digestion was performed at 37°C for 30 mm after adding 200 p1 of a mixture of 5 U/rn! RNase A and 200 U/mI RNase Ti to the hybridization mix. Protected fragments were precipitated with 300~ul Ambion RNase inactivation/precipitation buffer using 10~ig of yeast tRNA and 60 ,ug of glycogen as carriers. RNA was resuspended in 8 ,ul of gel loading buffer, heat denatured at 90°Cfor 3 mm, and fractionated on a 5% po!yacry!amide ge! containing 8 M urea. Gels were dried at 80°Cunder vacuum and exposed to film for 4-12 h. To quantify the levels of mRNA, the gels were digitized using a Phosphorlmager (Molecular Dynamics). The size of each probe and protected fragment was determined by comparison with samples of pBR322 digested with MspI (New England BioLabs) end labeled with [ 32Pl-dCTP using the K!enow enzyme (Boehninger Mannheim, Germany) for 30 mm at 37°C,and purified over a NucTrap column.
Biosynthetic labeling of dispersed intermediate pituitary cells
After dissection, the neurointermediate lobes were transferred to Eppendorf tubes and dispersed in Dulbecco' s modified Eagle medium (DMEM) -air containing 5 mg /ml trypsin (ICN Biochemicals, Cleveland, OH, U.S.A.) for 15 mm at 3 7°C.After this incubation, trypsin was diluted with DMEMair and the cells were collected by centrifugation at 100 g for 10 mm. The dispersed cells were resuspended in methionine-free DMEM containing 1 mg/ml type II-L lima bean trypsin inhibitor and 2 mg/ml bovine serum albumin (Sigma Chemical Co., St. Louis, MO, U.S.A.), transferred to a new tube (leaving behind the neural lobes), and collected by centnifugation.
For biosynthetic !abeling, dispersed intermediate pituitary cells were incubated in methionine-free complete serumfree medium (CSFM) containing 500 pCi [35SI methionine/ cysteine labeling mix (10~iMmethionine, 1,000 Ci/mmol; Amersham Corp., Arlington Heights, IL, U.S.A.) for 20 mm in a 5% CO 2 atmosphere. CSFM contains 0.3 mM cysteine, meaning that essentially al! of the !abel incorporated into proteins is [ 35SI methionine; even in methionine/cysteinefree CSFM, incorporation of!abe!ed [35S]cysteine is negligible (Zhou and Mains, 1994) . At the end of the pulse incubation with [35S]methionine/cysteine, the cells were pelleted and extracted immediately in boi!ing sodium dodecyl sulfate-PAGE (SDS-PAGE) buffer (50 mM sodium phosphate, pH 6.8, containing 1% SDS, 50 mM /3-mercaptoethanol, and 2 mM EDTA). Samples were heated to 95°Cfor 5 mm and stored at -80°C.In pilot experiments, we labe!ed intact neurointenmediate lobes from contro! or drug-treated animals; incorporation of [35SI methionine into tnichloroacetic acid precipitable material and into POMC was highly variab!e; acute!y dispersed cells gave much more reproducible results.
Immunoprecipitations
After the SDS//3-rnercaptoethanol extraction, a sevenfold excess of Nonidet P-40 over SDS was added and the samples were di!uted fivefold with 50 mM sodium phosphate, pH 7.4, containing 1% Triton X-!00 (Super E) plus pheny!methylsulfonyl fluoride (30~ig/ml). All samples were centrifuged at 14,000 g for 5 mm to pe!let-insolub!e material and the supernatants were analyzed by immunoprecipitation.
The radiolabe!ed proteins were immunoprecipitated using rabbit polyclonal antisera against the following: peptidyl-a-hydroxyglycine a-amidating lyase (PAL), Ab877 [rPAM-1(498-604)1; amino-terminal region of ACTH (AbJH93); PC!, ]; and PC2, Ab!!59[rPC2(626-638)1 (Milgramet al., 1993; Zhou and Mains, 1994) . The amount of antiserum necessary for quantitative immunoprecipitation of the proteins was determined by immunotitration of POMC, the most prevalent protein in melanotropes. After immunoprecipitation of labeled POMC with a fixed amount of antiserum, the supernatant was incubated with an additional amount of antiserum to immunoprecipitate any remaining POMC. No detectable POMC was left after the first immunoprecipitation, when 5 p1 of antiserum was used with 1% of a neurointermediate lobe. An excess of antiserum (10 iiI) was used to consistent!y immunoprecipitate each protein. Immune complexes were collected after incubation with 20 p1 protein A-Sepharose beads (Sigma) in Super E. POMC was immunoprecipitated from 1% of the cell extract. The remainder of the sample was used for sequentia! immunoprecipitation of PCi, PC2, and PAM. The proteins were released from the beads by boiling into SDS sample buffer, and analyzed on 10% polyacrylamide, 0.25% N,N'-methylene-bisacrylamide-SDS gels (Laemm!i, 1970) . Gels were fixed in 30% isopropanol, 10% acetic acid, and incubated with Amplify (Amersham) for fluorography. Quantitative ana!ysis of the samples was performed using a PhosphorImager (Molecular Dynamics).
Statistical analysis
For statistical analysis of mRNA levels and protein biosynthetic rates, the t test (two sample, one tail) was calculated using Excel 5.0.
RESULTS
The relatively homogeneous population of me!anotropes in the neurointermediate lobe of the pituitary provides a model system for studying the coordinate regulation of enzymes involved in the processing of neuropeptides. Most of the processing enzymes are known and the chronic effects of dopaminergic treatment on POMC and severa! processing enzymes have been described Bloomquist et al., 1991) . We set out to evaluate the short-term effects of dopaminergic treatment on these peptidergic cells. The effects of bromocriptine and ha!operido! treatments were evaluated by measuring levels of mRNA encoding POMC and peptidergic processing enzymes using RNase protection assays. The invo!vement of trans!ationa! effects was evaluated by measuring the biosynthetic rates of POMC, PCI, PC2, and PAM.
Transcript levels begin to change within a day of drug treatment
In previous studies, the levels of POMC mRNA approximately doubled after 21 days of haloperidol treatment (dopamine antagonist), whereas 21 days of treatment with a dopamine agonist caused a two-to fourfold diminution of POMC mRNA (Ho!!t et a!., 1982; Chen et a!., 1983; Kelsey et a!., 1986; Bloomquist et al., 1991) . Based on these findings, the time course of dopaminergic regulation of expression of a set of mRNAs encoding POMC and peptidergic processing enzymes was studied in vivo. A!! animals received five daily injections, with drug treatments given five times (5 days), two times (28 h), once (4 or 1 h), or not at all (saline); control rats received no injections. Total RNA isolated from the neurointermediate lobes of these rats was subjected to multiplex RNase protection analysis by hybridizing one set of samples to POMC, PAM, and CPH niboprobes and another set of samples to PCI, PC2, and Cytb 56, riboprobes. The ribosoma! protein S26 is expressed at comparable levels in many tissues (Vincent et al., 1993) ; analysis of S26 RNA in 5~ig RNA from control rats or rats treated with bromocriptine or haloperidol demonstrated no change in levels of S26 mRNA (data not shown). Thus, S26 riboprobe was also added to each sample as an internal control allowing us to measure simultaneously the levels of these transcripts and to correct for recovery. Representative autoradiographs demonstrating protected fragments of POMC and peptidergic processing enzymes are shown in Fig. 2 . The sizes of each of the fragments obtained after RNase digestion were as expected. The assay was linear over the range of 50-1,000 pg of POMC RNA, 5-50 pg of the other RNAs, and was linear in the range of total RNA analyzed.
As shown in Fig. 3 , significant changes in the levels of POMC mRNA were first observed after two injections (28 h sample) of bromocriptine with levels of POMC mRNA dec!ining to about two-thirds of control values. After five daily injections of bromocriptine, levels of POMC transcript further decreased to about one-third of control. In contrast, haloperido! treatment caused a slight increase (maximum, I .6-fo!d) in the levels of POMC mRNA, with little change between 28 h and 5 days. In previous studies (Ho!lt et al., 1982; B!oomquist et a!., 1991), longer term (3 weeks) treatment of male rats with haloperido! caused at most, a twofold increase in POMC mRNA levels. Levels of POMC transcript were approximately fivefold higher in haloperido! versus bromocriptine-treated rats after 5 days.
Levels of peptidergic processing enzyme mRNA were determined after the same bromocriptine or haloperido! treatment paradigm. Significant decreases in levels of PC2, CPH, and PAM mRNA were detectable within 4 h of bromocriptine treatment. After 5 days of treatment with bromocriptine, levels of PC2, CPH, and PAM transcripts decreased to about one-half of control levels, whereas the levels of PCI transcript were less affected and levels of Cytb561 transcript were not significantly decreased. Ha!operidol treatment caused a slight but significant increase in the levels of PC2 and PC! mRNAs, whereas levels of PAM, CPH, and Cytb561 mRNA were not significantly affected. Thus, treatment with bromocriptine brought about parallel decreases in the levels of POMC and PC2 mRNA, with PAM, CPH, and PCi being less affected and Cytb561 unaffected. Treatment with haloperidol had the   FIG. 4 . Level of P0MG and processing enzyme mRNAs in control neurointermediate pituitaries. Total RNA was isolated from control neurointermediate lobes (n = 5) and subjected to multiplex RNase protection analysis and quantification with a Phosphorlmager to determine the level of each transcript indicated. After quantification, the molecules of mRNA/cell were calculated using a yield of 5 ig RNA per neurointermediate lobe and published values of 3 x iOmelanotropes/adult male rat neurointermediate lobe (Mains et al., 1987; Back, 1989; Back and Soinila, 1994) . Note logarithmic scale for they axis. Each bar represents the mean ±SEM of five independent experiments. opposite effect on levels of each of these transcripts. It is interesting that the data demonstrate coordinate regulation of peptide precursor and some, but not a!!, of the processing enzymes in the neurointermediate pituitary.
Because RNase protection analysis provides an absolute measure of the amount of mRNA, we used the data from control animals to calculate the relative molar amounts of each transcript in the neurointermediate pituitary. As shown in Fig. 4 , POMC transcripts were '-.~200-fo!dmore prevalent than PC2 and CPH transcripts, and 1,000-fold more prevalent than PAM, PC1, or Cytb561 transcripts. Using our observed recovery of 5 ,ug total RNA per neurointermediate lobe and the literature values for the number of melanotropes per neurointermediate lobe (Mains et al., 1987; Back, 1989; Back and Soinila, 1994) , we determined the number of molecules of mRNA/me!anotrope. The number of POMC transcripts per cell is estimated to be 31,000, with less prevalent transcripts such as PC 1 and PAM present in the range of 20-30 mRNA molecules per melanotrope. These results are consistent with the expression of both PCi and PC2 in intermediate me!anotropes, with PC2 being more abundant (Seidah et a!., 1990; Bloomquist et a!., 1991; Day et a!., 1992).
Dopaminergic treatment has a translational effect on expression of POMC and processing enzymes
Although we observed that dopaminergic agents have an effect on mRNA levels, several observations indicated that dopaminergic agents might have an additional effect on the biosynthesis of POMC and its product peptides at the translational level as well (Beau!ieu To evaluate the effect of bromocniptine and haloperido! treatment on the rate at which POMC and processing enzymes are synthesized, dispersed melanotropes prepared from haloperidol-and bromocriptine-treated rats were incubated for 20 mm in medium containing [355] methionine, extracted with boiling SDS-PAGE buffer, and immunoprecipitated with antisera to POMC, PC!, PC2, and PAM.
The two forms of POMC resolved by SDS-PAGE represent POMC molecules containing glycosylated and nong!ycosylated ACTH. When the effect of treatment with bromocriptine was evaluated after 4 h, 28 h, or 5 days, a significant decrease in the biosynthetic rate of POMC was observed (Fig. 5A) . To determine how rapidly the effect of bromocriptine could be observed, metabolic labeling studies were performed 1 and 4 h after a single injection of drug. Consistent decreases in the biosynthetic rate of POMC were observed as early as 4 h, but not I h, after a single injection of bromocriptine (Fig. SB) . It is interesting that the levels of POMC mRNA did not decrease significantly until the 28-h time point (Figs. 2 and 3) , indicating that bromocriptine decreased the biosynthetic rate of POMC before changes in POMC mRNA were detectable. Ha!operidol treatment caused a severalfold increase in the biosynthetic rate of POMC (Fig.  SA) , an effect that was first observed at the 28-h time point and was far greater in magnitude than the effect of haloperidol on POMC mRNA levels (Fig. 3) . A single injection of haloperido! did not produce consistent changes in the biosynthetic rate of POMC at 1 or 4 h after treatment. The translational effect of haloperidol treatment appeared at a later time than the translational effect of bromocriptine (4 h).
Similar effects on the biosynthetic rate of peptidergic processing enzymes were observed after bromocriptine and haloperidol treatment. The biosynthesis of endogenous or transfected PCI, PC2, and PAM in AtT-20 cells has been characterized previously Zhou et a!., 1993; Zhou and Mains, 1994) . The antisera used in these studies were used to immunoprecipitate PC2, PCi, and PAM from lysates of me!-anotropes. The antiserum to PC2 yielded a single band of 76-kDa proPC2, whereas antiserum to PCI yielded proPCl and PCi at 87 and 81 kDa, respectively (Fig.  6) . Three major forms of PAM mRNA occur in melanotropes, and PAM-i (120 kDa), PAM-2 (105 kDa), and small amounts of newly synthesized PAM-3 were detected (Fig. 6A, B) . Bromocriptine treatment consistently decreased the biosynthetic rate of PC2 at the 4-h time point but not at the 1-h time point (Fig. 6A) . After a time course similar to the one observed for POMC biosynthesis, a significant effect of haloperidol treatment of the biosynthetic rate of PC2 was first observed consistently at the 28-h time point (Fig. 6B) . Similar changes were observed in the biosynthesis of PCi and PAM (Fig. 6B) . The longer exposure times used for the fiuorographs showing PCi and PAM reflect the lower levels of these proteins in neurointermediate pituitary when compared with PC2 and POMC.
The biosynthetic rate of each immunoprecipitable protein after the drug treatments was quantified using a Phosphorlmager. The biosynthetic rate of POMC was decreased to one-halfof control levels 4 h after a single bromocniptine treatment (Fig. 7) . After 28 h of bromocriptine treatment, the biosynthetic rate of POMC was further decreased to about one-fifth of control. The biosynthetic rate of PC2 was also decreased approximately twofold 4 h after a single injection of bromocriptine; however, no significant changes were observed at the 28-h time point after two drug treatments. Changes in PC1 biosynthesis were similar to the changes observed for PC2 (data not shown). The biosynthetic rate of PAM was decreased to two-thirds of control 4 h after a single injection of bromocriptine and was not further diminished after longer drug treatment (data not shown).
In rats treated with haloperido! for 28 h, the biosynthesis of POMC increased four-to sixfold despite only a 1.6-fold increase in POMC mRNA levels. Similar changes were observed for the biosynthetic rates of PC2 (Fig. 7) , PCi, and PAM (data not shown). Haloperidol treatment affects the biosynthetic rate of POMC, PCi, PC2, and PAM much more dramatically than the mRNA levels; dopaminergic regulation of melanotropes involves a substantial translational effect.
By contrast, overall protein synthesis was not significantly affected by manipulation of the dopaminergic system. To ascertain the effect of the 28-h bromocriptine or haloperidol treatment on overall protein synthesis in melanotropes, the total extract after a 20-mm incubation with [355] methionine was analyzed by two-dimensional PAGE. When the newly synthesized proteins from control and drug-treated intermediate pituitary cells were compared, only a subset of the proteins showed an effect of drug treatment on their synthesis. We compared the intensities of >100 well-resolved prevalent proteins in extracts of melanotropes from rats treated with bromocriptmne or haloperidol (data not shown); the intensities of <10% of these proteins were significantly altered after ha!operidol or bromocriptine treatment. It is interesting that three proteins showed a significant increase in synthesis with bromocriptine treatment and were not detectable in melanotropes from control animals or after treatment with haloperidol.
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FIG.
7. Quantification of the biosynthetic rate of P0MG and processing enzymes after drug treatment. Radiolabeled proteins immunoprecipitated from control and drug-treated melanotropes were fractionated on 10% SDS-polyacrylamide gels.
Quantitative analysis of samples such as those shown in Fig. 5 was performed using a Phosphorlmager. Relative biosynthetic rates were calculated. Similar results were obtained in three independent experiments. Data points that differ significantly from control (p < 0.05) are indicated by asterisks(*). HALO, haloperidol; BROMO, bromocriptine.
Because the methionine content of POMC, PCi, PC2, and PAM is known (Fig. 1) , the molar ratio of these newly synthesized proteins was determined. In control neurointermediate pituitaries (Fig. 8) , POMC molecules were synthesized '-1,500-fold more often than molecules of PC2, 3,000-fold more often than PCI molecules, and 10,000-fold more often than PAM molecules. If one assumes that biosynthetic rates reflect steady-state levels of each protein, one can use literature values for secretory granule content of POMC products (10,000 molecules/granule) (Back, 1989) to calculate the relative amount of the other proteins per secretory granule. It is striking that none of the processing enzymes would occur at a level higher than 10 molecules per granule, with only one molecule of PAM per granule.
DISCUSSION
One key question addressed in this study about dopaminergic regulation in the intermediate pituitary is whether there is coordinate regulation of the expression of peptidergic processing enzymes. We first evaluated the time course with which treatment with bromocniptine and haloperido! affects the level of mRNA encoding several granule-associated proteins. The steadystate level of each mRNA reflects the rate of transcription and the rate of degradation. The response patterns fell into the following three categories: changes in levels of POMC and PC2 mRNA were the largest and were similar in magnitude; smaller changes were observed in levels of mRNA for PCI, CPH, and PAM mRNA; and Cytb 561 mRNA levels were unchanged.
After treatment with bromocniptine or haloperido! for 3 weeks (Holit et al., 1982; B!oomquist et al., 1991) , POMC, PC2, and PAM mRNA levels showed changes similar in magnitude to the ones observed after 5 days of treatment; levels of PCi mRNA changed twofold after the chronic treatment with haloperidol. It is interesting that levels of POMC, PCi, and PAM mRNA were also regulated in parallel in AtT-20 corticotrope tumor cells, with a decrease in a!! three transcripts after glucocorticoid treatment and an increase in a!! three after corticotropin-releasing factor treatment (Mains and Eipper, 1984; Thie!e and Eipper, 1990; B!oomquist et a!., 1991) . Although levels of CPH mRNA were not affected by treatment with these secretagogues, CPH expression was subject to regulation by nicotine in chromaffin cells (Hook and Eiden, 1985) , depolarization in PC12 cells (Das et a!., 1992) , and osmotic stimulation in oxytocin-and vasopressin-producing ethionine for 20 mm before extraction with SDS sample buffer. P0MG immunoprecipitations were performed on 1% of the cell extract. The remainder of the sample was used for sequential immunoprecipitation of PG1, PG2, and PAM. After immunoprecipitation, the samples were fractionated by SDS-PAGE on a 10% gel and quantified using a Phosphorimager. Relative metabolic rates were calculated considering the number of methionines per protein (Fig. 1) and the amount of sample analyzed. As there are 3,000-10,000 molecules of P0MG per granule (Back, 1989) , the values were scaled to 10,000 molecules of P0MG. Note the logarithmic scale for they axis. The data shown represent mean ±SEM values of three independent experiments.
FIG. 9.
Effect of drug treatment on ratio of protein synthesis to mRNA level for P0MG and PG2. For better visualization of the early translational effects observed after treatment with bromocriptine (BROMO) or haloperidol (HALO), the relative ratios of protein synthesis to mRNA levels from three sets of experiments were determined using the data obtained after RNase protection analyses (Fig. 3 ) and metabolic labeling analyses (Fig. 7) .
magnoce!lu!ar neurons (Bondy et a!., 1989) . In genera!, changes in prohormone mRNA are greater in magnitude than changes in processing enzyme mRNAs.
Significant increases in the levels of POMC and processing enzyme mRNA were first observed 4 h after the second injection of haloperidol (28 h). No change in mRNA levels was observed 4 h after haloperidol treatment. Using dot blot hybridization, Chen et al. (1983) first detected an increase in POMC mRNA levels 6 h after haloperido! treatment. We observed that bromocriptine treatment brought about a significant decrease in levels of POMC and processing enzyme mRNA within 4 h. The half-life of POMC transcripts is 16-24 h (Roberts et al., 1979; Birnberg et a!., 1983) and the half-life of PAM transcripts is '=20 h (Maltese et al., 1996) . If transcription were halted immediately, levels of an mRNA whose half-life is 20 h would only decrease by 10% after 4 h. If bromocriptine affects mRNA levels by decreasing transcription without increasing turnover, the effects must be rapid.
Haloperido! treatment brought about a much bigger increase in the biosynthetic rate of POMC, PCi, PC2, and PAM proteins than predicted based on the mRNA levels. The increase in biosynthetic rate versus mRNA level was not apparent at 4 h but was clearly evident at 28 h (Fig. 9) . For POMC and PC2, biosynthetic rates were increased approximately four times over that predicted by mRNA level after 28 h of haloperidol treatment. Thus, regulation by haloperidol occurs at the translational level as well as the transcriptional level. In addition, bromocriptine treatment produced a rapid decrease in the biosynthetic rates of the granuleassociated proteins at 4 h after treatment (Fig. 7) , and that decline in biosynthetic rate was not entirely explained by a decrease in mRNA levels (Fig. 9) . After 28 h of bromocriptine treatment, biosynthetic rates more closely reflected mRNA levels. These resu!ts indicate that the response of melanotropes to bromocriptine and ha!operido! involves early translational effects, in addition to longer term effects on mRNA levels.
We previously used the fact that long-term regulation by bromocriptine or haloperido! is specific to a subset of the proteins expressed in melanotropes to clone novel neuroendocrine proteins (B!oomquist et al., 1994) . Our current metabolic labeling studies indicate that the short-term translational response of me!anotropes to dopaminergic agents is also limited to a subset of the proteins expressed. Initiation of protein synthesis, the rate-limiting step in translation, is extensively regulated (Hershey, 1991; Kozak, 1991; Proud, 1994; Hentze, 1995) . This process can involve the recognition of sequences and structural elements in specific mRNA molecules (McCarthy and Kolimus, 1995) . A unique eight-nucleotide sequence present three times in the 5 '-noncoding region of the preprosomastostatin II mRNA has been implicated as a regulatory site for interaction with putative trans-acting factors (Danoff and Shields, 1988) . On the other hand, secondary structures in the S '-untranslated region of mRNAs can control translation by modulating ribosome/mRNA interactions (Kozak, 1991) . Structural mapping of the porcine POMC mRNA indicates that nucleotide sequences in the 5 '-untranslated region can form a stable hairpin structure (Chevrier et al., 1988) .
Deletions of nucleotide sequences in the 5 '-untrans-!ated regions of the POMC and preprosomatostatin II mRNAs greatly increase the translational efficiency of these mRNAs. Insulin, which can stimulate overall translation rates as we!! as translation of specific mRNAs, stimulates phosphorylation of a protein that interacts with the translation initiation factor elF-4E, inducing its dissociation and enhancing translation (Pause et a!., 1994) . Translation of mRNAs with a highly structured 5 '-UTR can thus be selectively stimulated by insulin (Shantz and Pegg, 1994) .
The coordinate regulation of a prohormone and its processing enzymes has also been observed in pancreatic j3 cells (Martin et al., 1994; Alarcon et al., 1993) and adrenal chromaffin cells (Laslop et al., 1994) . Like POMC, insulin is synthesized as a prohormone and then processed to its active form by the action of PCi and PC2 Steiner et a!., i993b) . It is interesting that the biosynthesis of both PCi and PC2 is stimulated in parallel to the biosynthesis of proinsulin by elevated glucose (A!arcon et al., 1993; Martin et a!., 1994) . The stimulation of PCi and proinsulin biosynthesis is not affected by the presence of actinomycin D, indicating that regulation occurs at a translational level (Alarcon et a!., 1993) .
Although the translational effect ofglucose on PC 1 and proinsulin has been well documented, the mechanism underlying this regulation is still under investigation (Alarcon eta!., 1993) . In response to elevated glucose, /3 cells exhibit a rapid, coordinate increase in the bio-I. Neurochem., Vol. 67, No. 1, 1996 synthesis of 25 of the 32 major granule proteins resolved on two-dimensional gels (Guest et a!., 1991) , indicating the specificity of glucose regulation. In rat adrenal chromaffin cells, reserpine increased the levels of mRNAs encoding proneuropeptide Y, secretogranin II, PC2, CPH, PAM, and chromogranin A and B; expression of Cytb 561 was not affected by reserpine (Laslop et al., 1994) .
Studies examining the effect of exogenous processing enzyme expression clearly indicate that the level of expression is an important determinant of the cleavages observed (B!oomquist et a!., 1991; Thomas et al., 1991; Seidah et al., 1993; Zhou et a!., 1993) . The intermediate pituitary is one of the few systems in which it is possible to obtain enzyme-to-substrate ratios. POMC mRNA is known to comprise -~10% of the mRNA in melanotropes (Bloomquist eta!., 1991) . Our data are consistent with this estimate. When the synthetic rate of POMC was compared with that of PC!, PC2, or PAM, we observed that POMC was synthesized 1,000-fold more often than PC2, 3,000-fold more often than PCi, and 10,000-fold more often than PAM. Given the prevalence of each of the mRNAs, the synthetic rates suggest that POMC (900 nt), PC2 (2,500 nt), PCi (3,000 nt), and PAM (4,500 nt) mRNAs are translated with very similar efficiency. It is interesting that the ratio of POMC synthesis to synthesis of the most prevalent known endoprotease in melanotropes, PC2, is much higher than the ratio of POMC synthesis to PCI synthesis in AtT-20 corticotrope tumor cells (five molecules of POMC for every one molecule of PCi synthesized) (Zhou and Mains, 1994) . The molar ratio of POMC to PAM molecules in AtT-20 cells was previously established to be '=3,000:1 (Mains and Eipper, 1990 ); this ratio is quite comparable with the ratio obtained in me!anotropes.
Because the amount of each processing enzyme is relatively low, treatments that selectively change enzyme level or enzyme activity may affect the level of active peptide produced (Bloomquist et a!., 1991) .
Our studies indicate that translational effects play a major role in the regulation of protein expression of processing enzymes in melanotropes in response to bromocriptine and haloperidol. The mechanisms by which these rapid translational effects are generated must be explored. Me!anotropes in primary culture may be a useful too! in defining the mechanisms involved in the regulation of processing enzyme expression.
